Literature DB >> 21240982

Treatment and outcome of parosteal osteosarcoma: biological versus endoprosthetic reconstruction.

Philipp T Funovics1, Frederik Bucher, Cyril D Toma, Rainer I Kotz, Martin Dominkus.   

Abstract

BACKGROUND AND OBJECTIVES: Due to its good prognosis despite local recurrence, more and less invasive methods for surgical treatment of parosteal osteosarcoma (POS) have been described. Aim of this retrospective single-center study was to investigate differences in outcome after biological and prosthetic reconstruction.
METHODS: A total of 28 patients with POS, 14 females, 14 males, mean age of 27 years (median, 24 years; range 15-59 years), mean follow-up of 130 months (median, 104 months; range, 9-383 months), underwent wide tumor resection and prosthetic reconstruction (12 patients, 42.9%), less extensive resection and biological reconstruction (11 patients, 39.3%), rotationplasty (three patients, 10.7%), or amputation (two patients, 7.1%).
RESULTS: There were two cases of local recurrence in patients with biological reconstruction and three cases of pulmonary metastases, leading to death of disease in two. Ten-year disease-specific survival was 91.1%. There was no significant difference between prosthetic and biological reconstruction in terms of local recurrence, metastasis, or functional outcome (mean MSTS Score, 85%). There were significantly more revisions in prosthetic reconstructions.
CONCLUSIONS: Given that the resection of the tumor has clear margins, both prosthetic and biological reconstruction show similar results; prostheses allow better local tumor control, however, require more revisions over time.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21240982     DOI: 10.1002/jso.21859

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  9 in total

1.  Progress in musculoskeletal oncology from 1922 - 2012.

Authors:  Rainer I Kotz
Journal:  Int Orthop       Date:  2014-05       Impact factor: 3.075

2.  Primary parosteal osteosarcoma of the rib.

Authors:  Abhishek Shah; Hongxi Ma; Xiaoyan Sun; Dianbo Cao
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-04-18

3.  Oncological and Functional Outcomes after Hemicortical Resection and Biological Reconstruction Using Allograft for Parosteal Osteosarcoma of the Distal Femur.

Authors:  Olga D Savvidou; Stavros Goumenos; Ioannis Trikoupis; Angelos Kaspiris; Dimitra Melissaridou; Panagiotis Gavriil; Jimmy Georgoulis; Panayiotis J Papagelopoulos
Journal:  Sarcoma       Date:  2022-06-02

4.  Primary malignant tumours of the scapula--a review of 29 cases.

Authors:  Stephan E Puchner; Joannis Panotopoulos; Rudolf Puchner; Reinhard Schuh; Reinhard Windhager; Philipp T Funovics
Journal:  Int Orthop       Date:  2014-06-25       Impact factor: 3.075

5.  The Significance of a "Close" Margin in Extremity Sarcoma: A Systematic Review.

Authors:  Ike Hasley; Yubo Gao; Amy E Blevins; Benjamin J Miller
Journal:  Iowa Orthop J       Date:  2018

6.  Long-Term Functional Outcomes of Distal Femoral Replacements Compared to Geographic Resections for Parosteal Osteosarcomas of the Distal Femur.

Authors:  Benjamin K Wilke; Anna R Cooper; C Parker Gibbs; Mark T Scarborough; Andre R Spiguel
Journal:  Iowa Orthop J       Date:  2018

7.  Surgical and Functional Outcome after Endoprosthetic Reconstruction in Patients with Osteosarcoma of the Humerus.

Authors:  Christoph Böhler; Stephan Brönimann; Alexandra Kaider; Stephan E Puchner; Irene K Sigmund; Reinhard Windhager; Philipp T Funovics
Journal:  Sci Rep       Date:  2018-11-08       Impact factor: 4.379

8.  Parosteal osteosarcoma of the fibula in a middle-aged patient: A case report.

Authors:  Guiping Chen; Qiang Xu; Bin Zhang; Min Dai
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

9.  Non-vascularised fibula grafts for reconstruction of segmental and hemicortical bone defects following meta- /diaphyseal tumour resection at the extremities.

Authors:  Ulrich Lenze; Stefanie Kasal; Fritz Hefti; Andreas Heinrich Krieg
Journal:  BMC Musculoskelet Disord       Date:  2017-07-05       Impact factor: 2.362

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.